- STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trialsNew GSK CEO Luke Miels outlined his strategy to help the company navigate a patent cliff and get on a path toward long-term growth.STAT · 48m ago↗ source
- Alnylam's stock is down 30% despite a booming biotech market. Here's why.Alnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A is up, IPOs are back with record-breaking for…Endpoints · 59m ago↗ source
- STAT+: FDA staff reiterate concerns about Replimune skin cancer treatmentRegulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its investigational skin cancer treatment.